Table 1.
Surveillance, Epidemiology, and End Results (SEER) Cancer Incidence Rate Trends With Joinpoint Analyses from 1992 to 2010 for the Most Common Cancers, by Sex, for All Racial and Ethnic Groups Combineda
|
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Joinpoint analyses (1992-2010)b |
||||||||||
| Trend 1 |
Trend 2 |
Trend 3 |
Trend 4 |
AAPCc |
||||||
| Sex/Cancer Site or Type | Years | APCd | Years | APCd | Years | APCd | Years | APCd | 2001 - 2010 |
2006 - 2010 |
| All sitese | ||||||||||
| Both sexes | 1992 - 1994 | −3.1 | 1994 - 1999 | 0.3 | 1999 - 2010 | −0.6 f | −0.6 g | −0.6 g | ||
| (Delay-adjusted) | 1992 - 1994 | −3.2 f | 1994 - 1998 | 0.4 | 1998 - 2010 | −0.4 f | −0.4 g | −0.4 g | ||
| Males | 1992 - 1994 | −5.8 f | 1994 - 2007 | −0.5 f | 2007 - 2010 | −2.2 f | −1.1 g | −1.8 g | ||
| (Delay-adjusted) | 1992 - 1994 | −5.6 f | 1994 - 2010 | −0.6 f | −0.6 g | −0.6 g | ||||
| Females | 1992 - 1998 | 0.7 f | 1998 - 2010 | −0.3 f | −0.3 g | −0.3 g | ||||
| (Delay-adjusted) | 1992 - 1994 | −0.4 | 1994 - 1998 | 1.2 | 1998 - 2003 | −0.8 f | 2003 - 2010 | 0.1 | −0.1 | 0.1 |
| Children (ages 0-14) | 1992 - 2010 | 0.8 f | 0.8 g | 0.8 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.8 f | 0.8 g | 0.8 g | ||||||
| Children (ages 0-19) | 1992 - 2010 | 0.7 f | 0.7 g | 0.7 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.8 f | 0.8 g | 0.8 g | ||||||
| Top 17 cancers for malesh | ||||||||||
| Prostate | 1992 - 1995 | −11.2 f | 1995 - 2000 | 2.2 | 2000 - 2010 | −2.2 f | −2.2 g | −2.2 g | ||
| (Delay-adjusted) | 1992 - 1995 | −11.2 f | 1995 - 2000 | 2.2 | 2000 - 2010 | −2.0 f | −2.0 g | −2.0 g | ||
| Lung and bronchus | 1992 - 2010 | −2.0 f | −2.0 g | −2.0 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | −1.9 f | −1.9 g | −1.9 g | ||||||
| Colon and rectum | 1992 - 1995 | −2.6 f | 1995 - 1998 | 1.4 | 1998 - 2008 | −2.5 f | 2008 - 2010 | −4.7 f | −3.0 g | −3.6 g |
| (Delay-adjusted) | 1992 - 1995 | −2.6 f | 1995 - 1998 | 1.4 | 1998 - 2008 | −2.5 f | 2008 - 2010 | −4.2 f | −2.9 g | −3.3 g |
| Urinary bladder | 1992 - 2010 | −0.1 | −0.1 | −0.1 | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.0 | 0.0 | 0.0 | ||||||
| Melanoma of the skin | 1992 - 2010 | 2.4 f | 2.4 g | 2.4 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | 2.4 f | 2.4 g | 2.4 g | ||||||
| Non-Hodgkin lymphoma | 1992 - 1995 | 2.8 | 1995 - 1998 | −2.1 | 1998 - 2010 | 0.5 f | 0.5 g | 0.5 g | ||
| (Delay-adjusted) | 1992 - 1995 | 2.8 | 1995 - 1998 | −2.2 | 1998 - 2010 | 0.7 f | 0.7 g | 0.7 g | ||
| Kidney and renal pelvis | 1992 - 2004 | 1.9 f | 2004 - 2008 | 4.5 f | 2008 - 2010 | −2.8 | 1.9 g | 0.8 | ||
| (Delay-adjusted) | 1992 - 2004 | 1.9 f | 2004 - 2008 | 4.7 f | 2008 - 2010 | −2.0 | 2.2 g | 1.3 | ||
| Oral cavity and pharynx | 1992 - 2003 | −1.5 f | 2003 - 2010 | 0.5 | 0.0 | 0.5 | ||||
| (Delay-adjusted) | 1992 - 2003 | −1.5 f | 2003 - 2010 | 0.7 | 0.2 | 0.7 | ||||
| Leukemia | 1992 - 2010 | −0.1 | −0.1 | −0.1 | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.4 f | 0.4 g | 0.4 g | ||||||
| Pancreas | 1992 - 2003 | 0.0 | 2003 - 2007 | 2.5 f | 2007 - 2010 | −1.2 | 0.7 | −0.3 | ||
| (Delay-adjusted) | 1992 - 2001 | 0.0 | 2001 - 2010 | 1.3 f | 1.3 g | 1.3 g | ||||
| Liver and intrahepatic bile duct | 1992 - 2010 | 3.5 f | 3.5 g | 3.5 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | 3.7 f | 3.7 g | 3.7 g | ||||||
| Stomach | 1992 - 2010 | −1.7 f | −1.7 g | −1.7 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | −1.7 f | −1.7 g | −1.7 g | ||||||
| Esophagus | 1992 - 2010 | −0.1 | −0.1 | −0.1 | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.0 | 0.0 | 0.0 | ||||||
| Brain and other nervous system | 1992 - 2010 | −0.3 f | −0.3 g | −0.3 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | −0.3 f | −0.3 g | −0.3 g | ||||||
| Myeloma | 1992 - 2010 | 0.5 f | 0.5 g | 0.5 g | ||||||
| (Delay-adjusted) | 1992 - 2006 | 0.4 | 2006 - 2010 | 3.5 f | 1.8 g | 3.5 g | ||||
| Larynx | 1992 - 2003 | −3.2 f | 2003 - 2010 | −1.6 f | −1.9 g | −1.6 g | ||||
| (Delay-adjusted) | 1992 - 2003 | −3.2 f | 2003 - 2010 | −1.5 f | −1.8 g | −1.5 g | ||||
| Thyroid | 1992 - 1996 | −1.0 | 1996 - 2010 | 5.4 f | 5.4 g | 5.4 g | ||||
| (Delay-adjusted) | 1992 - 1996 | −0.9 | 1996 - 2010 | 5.4 f | 5.4 g | 5.4 g | ||||
| Top 18 cancers for femalesh | ||||||||||
| Breast | 1992 - 1999 | 1.3 f | 1999 - 2004 | −2.2 f | 2004 - 2010 | 0.1 | −0.7 | 0.1 | ||
| (Delay-adjusted) | 1992 - 1999 | 1.3 f | 1999 - 2004 | −2.2 f | 2004 - 2010 | 0.2 | −0.6 | 0.2 | ||
| Lung and bronchus | 1992 - 2007 | 0.0 | 2007 - 2010 | −2.6 f | −0.9 g | −1.9 g | ||||
| (Delay-adjusted) | 1992 - 1998 | 0.8 f | 1998 - 2001 | −1.3 | 2001 - 2005 | 0.7 | 2005 - 2010 | −1.2 f | −0.4 | −1.2 g |
| Colon and rectum | 1992 - 1995 | −1.8 f | 1995 - 1998 | 1.8 | 1998 - 2008 | −2.0 f | 2008 - 2010 | −4.7 f | −2.6 g | −3.3 g |
| (Delay-adjusted) | 1992 - 1995 | −1.8 f | 1995 - 1998 | 1.8 | 1998 - 2008 | −1.9 f | 2008 - 2010 | −4.1 f | −2.4 g | −3.0 g |
| Corpus and uterus, NOS | 1992 - 2006 | −0.2 | 2006 - 2010 | 2.8 f | 1.1 g | 2.8 g | ||||
| (Delay-adjusted) | 1992 - 2006 | −0.2 | 2006 - 2010 | 2.9 f | 1.2 g | 2.9 g | ||||
| Thyroid | 1992 - 1998 | 3.9 f | 1998 - 2010 | 6.5 f | 6.5 g | 6.5 g | ||||
| (Delay-adjusted) | 1992 - 1998 | 3.9 f | 1998 - 2010 | 6.5 f | 6.5 g | 6.5 g | ||||
| Non-Hodgkin lymphoma | 1992 - 2003 | 1.3 f | 2003 - 2010 | −0.2 | 0.1 | −0.2 | ||||
| (Delay-adjusted) | 1992 - 2003 | 1.3 f | 2003 - 2010 | 0.0 | 0.3 | 0.0 | ||||
| Melanoma of the skin | 1992 - 1997 | 4.0 f | 1997 - 2010 | 1.6 f | 1.6 g | 1.6 g | ||||
| (Delay-adjusted) | 1992 - 1997 | 3.9 f | 1997 - 2010 | 1.7 f | 1.7 g | 1.7 g | ||||
| Ovarye | 1992 - 2010 | −1.0 f | −1.0 g | −1.0 g | ||||||
| (Delay-adjusted) ‡ | 1992 - 2010 | −0.9 f | −0.9 g | −0.9 g | ||||||
| Kidney and renal pelvis | 1992 - 1999 | 1.4 f | 1999 - 2008 | 3.4 f | 2008 - 2010 | −4.7 | 1.5 g | −0.7 | ||
| (Delay-adjusted) | 1992 - 2000 | 1.6 f | 2000 - 2008 | 3.6 f | 2008 - 2010 | −4.0 | 1.9 g | −0.2 | ||
| Pancreas | 1992 - 1999 | −0.2 | 1999 - 2010 | 1.1 f | 1.1 g | 1.1 g | ||||
| (Delay-adjusted) | 1992 - 2000 | −0.1 | 2000 - 2010 | 1.4 f | 1.4 g | 1.4 g | ||||
| Leukemia | 1992 - 2010 | 0.1 | 0.1 | 0.1 | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.6 f | 0.6 g | 0.6 g | ||||||
| Urinary bladder | 1992 - 2004 | −0.2 | 2004 - 2010 | −1.3 f | −0.9 g | −1.3 g | ||||
| (Delay-adjusted) | 1992 - 2010 | −0.4 f | −0.4 g | −0.4 g | ||||||
| Cervix uteri | 1992 - 2010 | −2.5 f | −2.5 g | −2.5 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | −2.5 f | −2.5 g | −2.5 g | ||||||
| Oral cavity and pharynx | 1992 - 2010 | −0.9 f | −0.9 g | −0.9 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | −0.9 f | −0.9 g | −0.9 g | ||||||
| Brain and other nervous system | 1992 - 2010 | −0.1 | −0.1 | −0.1 | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.0 | 0.0 | 0.0 | ||||||
| Myeloma | 1992 - 2010 | 0.1 | 0.1 | 0.1 | ||||||
| (Delay-adjusted) | 1992 - 2010 | 0.5 f | 0.5 g | 0.5 g | ||||||
| Stomach | 1992 - 2010 | −0.8 f | −0.8 g | −0.8 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | −0.7 f | −0.7 g | −0.7 g | ||||||
| Liver and intrahepatic bile duct | 1992 - 2010 | 2.8 f | 2.8 g | 2.8 g | ||||||
| (Delay-adjusted) | 1992 - 2010 | 2.9 f | 2.9 g | 2.9 g | ||||||
Abbreviations: AAPC, average annual percent change; APC, annual percent change; NOS, not otherwise specified.
Source: Surveillance, Epidemiology, and End Results (SEER) 13 areas covering about 14% of the US population (Connecticut, Hawaii, Iowa, Utah, and New Mexico, the Alaska Native Tumor Registry, rural Georgia, and the metropolitan areas of Los Angeles, Greater Bay, Detroit, Atlanta, and Seattle-Puget Sound).
Joinpoint analyses with up to 3 joinpoints yielding up to 4 trend segments (Trends 1-4) were based on rates per 100,000 persons and were age-adjusted to the 2000 US standard population (19 age groups: ages <1 year, 1-4 years, 5-9 years, …, 80-84 years, ≥85 years; Census publication p25-1130; US Bureau of the Census, Current Population Reports, p25-1130. Washington, DC: US Government Printing Office, 2000). For joinpoint analysis, the Joinpoint Regression Program was used (version 4.0.3, April 2013; Surveillance Research Program, National Cancer Institute, Bethesda, Md).
The AAPC is a weighted average of the APCs that is calculated by joinpoint regression.
The APC is based on rates that were age-adjusted to the 2000 US standard population (19 age groups; Census publication p25-1130).
All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
The APC is statistically significantly different from zero (2-sided t test; P < .05).
The AAPC is statistically significantly different from zero (2-sided Z test; P < .05).
Cancers are listed in descending rank order of sex-specific, age-adjusted incidence rates for 2006 through 2010 for all racial and ethnic groups combined (using data from the National Program of Cancer Registries [NPCR] and SEER Program areas reported by the North American Association of Central Cancer Registries [NAACCR] as meeting high-quality incidence data standards for 2006-2010). More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group.